What
are the compared deleterious effects of bile acids and
trypsin concentration
in the refluxate of animal models?
L.
CHEN(Piscatawa)
Does
reflux of duodenal content induce glandular metaplasia in animal models?
K.
MIWA (Kanazawa)
Can
the possibility of Barrett metaplasia developing from the stem cells in the esophageal
basal layer be envisaged consistent with experimental duodeno-esophageal reflux?
K.
MIWA(Kanazawa)
11:10 a.m.
Topic
Forum Barrett’s esophagus: is there a clinically
useful animal model at all? N. BUTTAR(Rochester
- MN) - L. CHEN (Piscataway)
11:25
a.m.
11:25 a.m.
11:30
a.m.
Y. ROMERO (USA)
What
is the prevalence of Barrett’s esophagus after total
gastrectomy?
A.
VANLAETHEM(La Louviere)
What
is the prevalence of alkaline material in Barrett patients?
H.J.
STEIN(Munich)
Compared
to patients with GERD, what is the spectrum of exposure of esophagus
to bilirubin in Barrett patients?
M. COSTANTINI(Padova)
Can
the respective roles of acid and bile in the development of Barrett’s
esophagus be assessed? Should a synergistic action be envisaged?
J.E.
RICHTER(Cleveland)
Is
the DGR Bilitec profile different in GERD patients with, and
without Barrett’s esophagus?
R.
ROMAGNOLI(Turin)
Is
there a different bilirubin exposure in long segment compared
to short segment Barrett’s esophagus?
C.G. BREMNER(Los Angeles)
Is
there a greater bilirubin exposure time in patients with complicated
Barrett’s esophagus?
T.N.
WALSH (Dublin)
What
is the relationship between carditis and Barrett metaplasia?
R.
GENTA, E.R. TSCHANZ (Geneva)
12:10 a.m.
12:25
a.m.
R.K. MITTAL(USA)
What
is the respective influence of reflux and H pylori in the
development of carditis?
R.H. RIDDELL (Toronto)
Can
a prophylactic effect of medical therapy on the development of
Barrett’s esophagus be envisaged?
S.J.
SONTAG(Hines)
Can a specific effect of PPIs on the development
of dysplasia be explained?
R.E. SAMPLINER(Tucson)
Is
there a place for a non endoscopic surveillance of these patients?
